NCT06529848 Impact of Exercise Training on Ischemia With Non-Obstructive Coronary Arteries (INOCA): The ExINOCA Study
| NCT ID | NCT06529848 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bispebjerg Hospital |
| Condition | Coronary Microvascular Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2027-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-11-01 with a primary completion date of 2027-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to identify causes of chest pain in patients experiencing chest pain with no signs of narrowing of the coronary arteries of the heart, and to investigate whether physical exercise can improve coronary microvascular function. Hypotheses: The first hypothesis is that in INOCA, with reduced function of microvasculature of the heart, this reduced function also occurs in other organs of the body. The second hypothesis is that regular physical activity (aerobic exercise training) can improve coronary microvascular function, reduce symptoms, and that there is a parallel improvement in vascular function in other organs of the body.
Eligibility Criteria
Inclusion Criteria: * Coronary microvascular dysfunction, defined as myocardial bloodflow reserve (MBFR) \< 2.5 or hyperemic myocar-dial blood flow (hMBF)\<2.3 ml/g/min using \[15O\]H2O-PET * No obstructive coronary artery disease Exclusion Criteria: * Females of childbearing potential (defined as a premeno-pausal female capable of becoming pregnant). The female patient must either be postmenopausal, defined as amen-orrhea for at least 1 year, or surgically sterile * Heart failure, defined as left ventricular ejection fraction of less than 40% * Uncontrolled hypertension defined as blood pressure above target 140/90 for all * Co-morbidity resulting in \<1 year expected survival * Considered by the investigator, for any reason, to be an un-suitable candidate for the study. * Unable or unwilling to exercise, e.g. due to arthritis or in-jury\* * Already are regularly physically active and/or have a maxi-mal oxygen uptake \>45 ml/kg/min
Contact & Investigator
Eva Prescott, MD, DMSc
PRINCIPAL INVESTIGATOR
University of Copenhagen
Frequently Asked Questions
Who can join the NCT06529848 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Coronary Microvascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06529848 currently recruiting?
Yes, NCT06529848 is actively recruiting participants. Contact the research team at Eva.Irene.Bossano.Prescott@regionh.dk for enrollment information.
Where is the NCT06529848 trial being conducted?
This trial is being conducted at Copenhagen, Denmark, Frederiksberg, Denmark.
Who is sponsoring the NCT06529848 clinical trial?
NCT06529848 is sponsored by Bispebjerg Hospital. The principal investigator is Eva Prescott, MD, DMSc at University of Copenhagen. The trial plans to enroll 100 participants.